Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics2023, 15, 2382.
Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics 2023, 15, 2382.
Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics2023, 15, 2382.
Guiselin, T.; Lecoutey, C.; Rochais, C.; Dallemagne, P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics 2023, 15, 2382.
Abstract
The multifactorial nature of some diseases, and in particular neurodegenerative diseases such as Alzheimer’s disease, frequently requires the use of several drugs. These drug cocktails are not without drawbacks in terms of increased adverse effects, drug-drug interactions or adherence to treatment. The concept of pleiotropic drugs, which combine, within a single molecule, several activities directed against distinct therapeutic targets, makes it possible to overcome some of these problems. In addition, these pleiotropic drugs, generally, lead to the expression of a synergy of effects, sometimes greater than that observed with a combination of drugs. This article will review, through recent examples, the different kinds of pleiotropic drugs being studied or already present on the market of medicines.
Keywords
Drug; Pleiotropic; Neurodegeneration; Alzheimer
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
